GSK’s Hogenhuis Joins Ultragenyx Pharma as Chief Operating Officer

Xconomy San Francisco — 

Wladimir Hogenhuis has been appointed chief operating officer of Novato, CA-based Ultragenyx Pharmaceutical (NASDAQ: RARE). Hogenhuis comes to the rare disease drug developer from GlaxoSmithKline (NYSE: GSK), where he was senior vice president and general manager, specialty franchise. In April, Ultragenyx won FDA approval for burosumab (Crysvita), a drug developed to treat the rare bone disease X-linked hypophosphatemia.